title: Tetomilast: new promise for phosphodiesterase-4 inhibitors?
abstract: BACKGROUND
  Tetomilast is a novel thiazole phosphodiesterase-4 (PDE-4) inhibitor, which may prove useful in both the treatment of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). Here, the authors review the pharmacology of the drug, and offer critical review of the available data for use of tetomilast in the treatment of IBD.
  
  
  METHODS
  Peer-reviewed publications, including Phase I and II clinical trials, all other formats included.
  
  
  CONCLUSIONS
  Tetomilast may be beneficial in IBD. Small differences in molecules and in recombinant proteins can translate into substantial differences in clinical effects and toxicity in IBD. This is a reasonable approach when exploring new options like tetomilast.
authors.affiliation: Virginia Commonwealth University Medical Center, VCUHS Center for Inflammatory Bowel Disease, MCV Campus, Box 980341, Richmond, VA 23298-0341, USA. sbickston@mcvh-vcu.edu
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Bickston
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Snider
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Kappus
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D058988:Phosphodiesterase 4 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D058988:Phosphodiesterase 4 Inhibitors; D013844:Thiazoles; C108965:tetomilast